Please use this identifier to cite or link to this item:
|Title:||Prostate Imaging Reporting and Data System score of four or more: active surveillance no more.|
|Other Authors:||Perera, Marlon|
Prostate Imaging Reporting and Data System
Prostate Cancer Intervention Versus Observation Trial
Australian Prostate Cancer Research Centre, Epworth Healthcare, Richmond, Victoria, Australia.
UroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australia
|Citation:||BJU Int. 2016 Jun 22.|
|Abstract:||The introduction of multiparametric MRI (mpMRI) has improved the diagnosis and risk stratification of intermediate- and high-risk prostate cancer. In addition to diagnosis, mpMRI has increasingly become a useful tool for monitoring the prostate cancer risk of patients on active surveillance (AS) programmes. A significant proportion of men on AS programmes have suspicious lesions on mpMRI . Accordingly, repeat mpMRI provides means of non-invasive assessment with the potential for fusion biopsy and preferential sampling of prostate cancer tissue. In 2012, the Prostate Imaging Reporting and Data System (PI-RADS) introduced standardised reporting of prostate mpMRI. PI-RADS 4 and 5 lesions have been classified as ‘clinically significant cancer is likely to be present’ and ‘clinically significant cancer is highly likely’, respectively. PI-RADS 4 and 5 lesions are being increasing correlated with intermediate- and high-grade prostate cancer. As recently discussed in Gleason pattern 4: active surveillance no more , patients with intermediate-risk prostate cancer are not suitable for AS. In light of this, the presence of PI-RADS 4 or 5 lesions in men enrolled on AS programmes for prostate cancer warrants concern.|
|Journal Title:||BJU International|
|Affiliated Organisations:||Department of Surgery, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.|
Department of Surgery, St Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.
Department of Cancer Surgery, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia.
Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia.
|Type of Clinical Study or Trial:||Review|
|Appears in Collections:||Cancer Services|
Epworth Prostate Centre
Files in This Item:
There are no files associated with this item.
Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.